Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study

被引:189
作者
Barreiro-de Acosta, Manuel [1 ]
Vallejo, Nicolau [1 ]
de la Iglesia, Daniel [1 ]
Uribarri, Laura [1 ]
Baston, Iria [1 ]
Ferreiro-Iglesias, Rocio [1 ]
Lorenzo, Aurelio [1 ]
Enrique Dominguez-Munoz, J. [1 ]
机构
[1] Univ Santiago, Clin Hosp, Dept Gastroenterol, FIENAD, Santiago De Compostela, Spain
关键词
INFLAMMATORY-BOWEL-DISEASE; EVIDENCE-BASED CONSENSUS; REMISSION; INFLIXIMAB; INDUCTION; THERAPY; ENDOSCOPY; PROGNOSIS; OUTCOMES;
D O I
10.1093/ecco-jcc/jjv158
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Mucosal healing in ulcerative colitis (UC) has become a common endpoint in most clinical trials and a relevant therapeutic goal in clinical practice. Despite important differences between endoscopic Mayo scores 0 and 1, both scores are considered as mucosal healing in most important trials. The aim of the present study was to evaluate the risk of relapse in UC patients according to the degree of mucosal healing (endoscopic Mayo scores of 0 and 1). Methods: A prospective longitudinal cohort study was designed. All UC patients who presented with mucosal healing at colonoscopy were consecutively included. Mucosal healing was defined as an endoscopic Mayo score of 0 or 1. Clinical relapse was defined as the need for therapy to induce remission, any treatment escalation, hospitalization or colectomy. All clinical relapses were evaluated at months 6 and 12 after study entry. Results were subjected to unconditional stepwise logistic and Kaplan-Meier regression analysis. Results: One hundred and eighty-seven consecutive UC patients (126 [67.3%] with Mayo score 0 and 61 [32.7%] with Mayo score 1) were included. Of patients with Mayo scores 0 and 1, 9.4 and 36.6% respectively presented a relapse during the first 6 months of follow-up (p < 0.001). The only factor independently associated with UC relapses in the multivariate analysis was an endoscopic Mayo score of 1 (odds ratio 6.27, 95% confidence interval 2.73-14.40, p < 0.001). Conclusions: Patients with an endoscopic Mayo score of 1 have a higher risk of relapse than those with a score of 0. The concept of mucosal healing should be limited to patients with an endoscopic Mayo score of 0.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 24 条
[1]   European evidence based consensus for endoscopy in inflammatory bowel disease [J].
Annese, Vito ;
Daperno, Marco ;
Rutter, Matthew D. ;
Amiot, Aurelien ;
Bossuyt, Peter ;
East, James ;
Ferrante, Marc ;
Goetz, Martin ;
Katsanos, Konstantinos H. ;
Kiesslich, Ralf ;
Ordas, Ingrid ;
Repici, Alessandro ;
Rosa, Bruno ;
Sebastian, Shaji ;
Kucharzik, Torsten ;
Eliakim, Rami .
JOURNAL OF CROHNS & COLITIS, 2013, 7 (12) :982-1018
[2]  
[Anonymous], 2014, ENDOSC CLIN N AM, DOI DOI 10.1016/J.GIEC.2014.03.005
[3]   Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis [J].
Barreiro-de Acosta, Manuel ;
Lorenzo, Aurelio ;
Mera, Jose ;
Enrique Dominguez-Munoz, J. .
JOURNAL OF CROHNS & COLITIS, 2009, 3 (04) :271-276
[4]   Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing [J].
Bessissow, Talat ;
Lemmens, Bart ;
Ferrante, Marc ;
Bisschops, Raf ;
Van Steen, Kristel ;
Geboes, Karel ;
Van Assche, Gert ;
Vermeire, Severine ;
Rutgeerts, Paul ;
De Hertogh, Gert .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11) :1684-1692
[5]   Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease [J].
Casellas, Francesc ;
Barreiro de Acosta, Manuel ;
Iglesias, Marta ;
Robles, Virginia ;
Nos, Pilar ;
Aguas, Mariam ;
Riestra, Sabino ;
de Francisco, Ruth ;
Papo, Michel ;
Borruel, Natalia .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (07) :762-769
[6]   Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis [J].
Colombel, Jean Frederic ;
Rutgeerts, Paul ;
Reinisch, Walter ;
Esser, Dirk ;
Wang, Yanxin ;
Lang, Yinghua ;
Marano, Colleen W. ;
Strauss, Richard ;
Oddens, Bjoern J. ;
Feagan, Brian G. ;
Hanauer, Stephen B. ;
Lichtenstein, Gary R. ;
Present, Daniel ;
Sands, Bruce E. ;
Sandborn, William J. .
GASTROENTEROLOGY, 2011, 141 (04) :1194-1201
[7]   Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis [J].
Dignass, Axel ;
Eliakim, Rami ;
Magro, Fernando ;
Maaser, Christian ;
Chowers, Yehuda ;
Geboes, Karel ;
Mantzaris, Gerassimos ;
Reinisch, Walter ;
Colombel, Jean-Frederic ;
Vermeire, Severine ;
Travis, Simon ;
Lindsay, James O. ;
Van Assche, Gert .
JOURNAL OF CROHNS & COLITIS, 2012, 6 (10) :965-990
[8]   Mucosal Healing in Ulcerative Colitis: Where do we Stand? [J].
Fiorino, Gionata ;
Cesarini, Monica ;
Indriolo, Amedeo ;
Malesci, Alberto .
CURRENT DRUG TARGETS, 2011, 12 (10) :1417-1423
[9]   Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort [J].
Froslie, Kathrine Frey ;
Jahnsen, Jorgen ;
Moum, Bjorn A. ;
Vatn, Morten H. .
GASTROENTEROLOGY, 2007, 133 (02) :412-422
[10]   Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis [J].
Ikeya, Kentaro ;
Sugimoto, Ken ;
Kawasaki, Shinsuke ;
Iida, Takayuki ;
Maruyama, Yasuhiko ;
Watanabe, Fumitoshi ;
Hanai, Hiroyuki .
DIGESTIVE AND LIVER DISEASE, 2015, 47 (05) :365-371